Parks OB, Kothamasu KS, Ziemba MJ, Benner M, Cristinziano M, Kantz S, Leger D, Li J, Patel D, Rabuse W, Sutton S, Wilson A, Baireddy P, Kamat AA, Callas MJ, Borges MJ, Scalia MN, Klenk E, Scherer G, Martinez MM, Grubb SR, Kaufmann N, Pruitt JN, Keiser CN. Exposure to cuticular bacteria can alter host behavior in a funnel-weaving spider. Curr Zool. 2018 Dec;64(6):721-6. doi: 10.1093/cz/zox064
Ensor CR, Iasella CJ, Harrigan (Zhang) KM, Morrell MR, Moore CA, Shigemura N, Zeevi A, McDyer JF, Venkataramanan R. Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. Am J Transplant. 2018 Jun;18(6):1527-33. doi: 10.1111/ajt.14723
Giergiczny M, Dekker T, Hess S, Chintakayala P. Testing the stability of utility parameters in repeated best, repeated best-worst and one-off best-worst studies. Eur J Trans Infra. 2017 Sep 1;17(4):457-76. doi: 10.18757/ejtir.2017.17.4.3209
Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Novick D, Reed C, Haro JM, Gonzalez-Pinto A, Perrin E, Aguado J, Tohen M. Comparison of olanzapine and risperidone in the EMBLEM study: translation of randomized controlled trial findings into clinical practice. Int Clin Psychopharmacol. 2010 Sep;25(5):257-63.
Rivero E, Varas-Lorenzo C, Maguire AR, Eisen HJ, Pedersen TR, Nashan B, Elkammas E. 10-Year predicted probability of coronary heart disease in renal transplant recipients treated with everolimus or mmf. Poster presented at the American Transplant Congress; April 2002. Washington, DC. [abstract] Am J Transplant. 2002; 2(Suppl 3):418.